Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. - Wikidata - wikimedia - TriplyDB

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.

http://www.wikidata.org/entity/Q33572246

about

Immunotherapy for cancer in the central nervous system: Current and future directions Regulation of Natural Killer Cell Function by STAT3 Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis Improving the clinical impact of biomaterials in cancer immunotherapy.Understanding the role of the kynurenine pathway in human breast cancer immunobiology Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages AhR-Mediated, Non-Genomic Modulation of IDO1 Function The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells Immunological Relevance of the Coevolution of IDO1 and AHR Loss of HIF-1α in macrophages attenuates AhR/ARNT-mediated tumorigenesis in a PAH-driven tumor model IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.Tryptophan-degrading enzymes in tumoral immune resistance.Aryl hydrocarbon receptor ligands in cancer: friend and foe.A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy IL-27 induces the expression of IDO and PD-L1 in human cancer cells.Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma Cancer prevention and therapy through the modulation of the tumor microenvironment.Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Learning from other diseases: protection and pathology in chronic fungal infections.Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions.The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas.Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.IL-1β As Mediator of Resolution That Reprograms Human Peripheral Monocytes toward a Suppressive Phenotype.Human Bone Marrow-Derived Mesenchymal Stromal Cells Differentially Inhibit Cytokine Production by Peripheral Blood Monocytes Subpopulations and Myeloid Dendritic Cells.T-cell activation or tolerization: the Yin and Yang of bacterial superantigens.Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway.Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study.Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.Xenobiotic-induced activation of human aryl hydrocarbon receptor target genes in Drosophila is mediated by the epigenetic chromatin modifiers.

P2860

Q26750765-B49C0438-8C6D-4E3F-9C2F-4DD856F0F7FA Q26752551-308EEC46-7100-48F4-90DF-4C3D7C6A7B14 Q26765777-714A58FA-F312-4B1A-8831-E656ACA38EFF Q26766267-4080F2B5-79FF-400A-B068-6A4B9B8BDA85 Q26773472-F1EE4244-66BC-4692-844A-301A5AAE40AE Q26783748-53D76C6C-CD40-406E-BC2B-22F1D3565D60 Q27693336-432A69B0-A2CF-4BF7-B388-DAF987F1DA81 Q28073631-C8561F29-4C42-435A-AEBF-A93ABAC56CB3 Q28547142-14E3E6FA-464E-4CB0-8A46-C635156BEC32 Q28654567-67FD78BC-913C-47C8-8B8D-811A5B8F1741 Q28828484-14474F08-53AC-4D5F-98EB-962F9C540F01 Q34483744-85F2B497-428C-4361-A232-430C691E7542 Q34512092-0AC716F5-4D90-424E-BB94-A145AA073371 Q34913785-33C185B6-5344-4DFD-ADC7-73C70BDA4B85 Q35042385-73BB4743-7C7E-4108-818A-4437C4A86533 Q35458027-F25ACE20-3D3E-421B-9C80-0C9C9271170D Q36544739-31C03E2A-F11C-4FA3-A05A-F417FBE5D809 Q36635458-9C5DE87B-991A-489D-BC29-184AEBF757A8 Q36685395-7AA570E9-9C86-46DA-BE56-00B2F17A855D Q36952693-8A2435B9-417C-4C5E-9042-2DDCB84AFCC0 Q37058267-5CAB5D36-63B1-4C73-8EAF-D2501FEDFE4C Q38268639-A74F84FD-F49C-4475-98AA-0D663E3E2860 Q38356502-D9296964-20DB-4BA5-83AD-49C31E9EE9C6 Q38571347-BEE8E5C8-190E-472A-A01F-A4277E5623CF Q38588803-EE3139D7-5FA5-4C91-9371-A3E1D8EDEF29 Q38620878-0D1FC8B9-AE3A-4CEC-80B4-8E2347B3DE92 Q38875015-0F9B42DA-215D-4632-ACB8-BF497D6615AD Q38983429-99AED1FA-B15A-4CD1-BAEB-9DF07B7B6E0F Q38998436-9E43EE10-F671-4811-93C2-E8BBD20BA8BA Q39404674-8C944FB9-3765-4E26-85F2-A74D4706914D Q39751334-81B0F968-0F84-4CE2-AF9D-877108D3CDD5 Q40086331-520F36AD-866D-4FB7-BE6C-042DBA09F396 Q40548665-F689A3DD-1B1F-45D5-8876-93FCFE48B554 Q40921883-4584CAD1-BB9E-4177-B075-73C7B62721F1 Q41147895-77367304-92BE-4E94-8285-2539C325191C Q41585035-3CBA5494-2F4F-44B0-9A91-87A2C642582F Q41820198-00195BEA-F712-4DC4-9BAE-C7E4C81EA78E Q46014755-E8B4BB4E-C849-4F0E-8A8B-86E03B8ECCE2 Q47115510-A4CF7660-9380-4A3C-B1C1-0526B54466E2 Q47134135-91BBE52B-CCB4-4411-9441-3AF9D1F73887

P2860

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.

http://www.wikidata.org/entity/Q33572246

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@ast

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@en

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@nl

type

label

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@ast

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@en

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@nl

prefLabel

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@ast

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@en

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@nl

P1433

Q33572246-77A71532-C15A-4032-94B4-DAF8E602A8ED

P1476

Q33572246-E616874B-3E34-4539-8235-667C3D752CDB

P2093

Q33572246-0A532C6F-B0C2-41DA-8D19-9D9843C97845

Q33572246-4E4EA125-AA15-4F5B-A382-0A2D2DD229C0

Q33572246-6EE5E53F-32EA-4F24-91B8-4953B508FA94

Q33572246-781035E7-65AF-409E-930F-1C0C240D8D8A

Q33572246-AE3471C3-5AB7-4422-8D84-B25ECD535F24

Q33572246-C0464467-B5A1-4F84-94DC-24EDF60A3B7E

Q33572246-D7D9C889-6084-401E-B498-2EE33565CF65

Q33572246-EB67F18A-456B-499E-84E9-170C491AD948

Q33572246-F21301C7-F0B4-4D02-8274-720B91DDD110

P2860

Q33572246-033409FD-0739-41C2-A875-11E52B0DB3BC

Q33572246-12A2AE61-994E-4C42-B013-A340C5078EE2

Q33572246-176E84A4-7015-4FBE-802B-84EC3D567BA7

Q33572246-1A2DF5C2-457C-4711-888D-0D767EA9B206

Q33572246-1A82919B-86C5-464A-96AB-2C2CAB85C6B6

Q33572246-2491120E-8422-44B6-839E-FC7A949B17D9

Q33572246-263218AD-AE05-40D9-A966-4A753B37E168

Q33572246-389846FB-CF49-45ED-BD59-AFDE7320E252

Q33572246-41A79713-9680-4B41-A251-0DE00CC6BDC5

Q33572246-4539F3D3-781B-48BD-A944-F5081223989A

P304

Q33572246-23E0D880-B831-4637-A978-D1A3EA25F362

P31

Q33572246-BE6B1C70-CEF7-4E6E-9F7A-F5242F040C9A

P356

Q33572246-40A06A13-5BED-4D3C-87B6-B856B64BE163

P407

Q33572246-5C40C494-96A4-45DC-B32A-B9063F200FDA

P433

Q33572246-82A3F8B8-A194-4C61-9F61-5B473E8D9E1C

P478

Q33572246-AD700711-4FA6-4379-9D3C-1B3DE98D70D7

P50

Q33572246-24CCB6D4-F66A-4AA8-AB2F-E145BC09CFDB

Q33572246-52685EB3-4FD2-4901-B0C7-AFE925D81625

Q33572246-92272CE8-CE8E-4BEF-B7F8-A0A72698BA90

Q33572246-9BD83CB2-FEDB-4964-B76F-936C90A3097A

Q33572246-9F90DEA2-3719-48DC-A5FE-77431818697D

Q33572246-C3238118-58A5-42E0-98DD-5ACE5A2522B2

Q33572246-FDC43A53-9A11-4BF5-9C1B-EBD2AE0440C3

P577

Q33572246-A916C1B9-5C71-4724-AAD9-FA672DBA991A

P5875

Q33572246-24B6EFDF-8EAC-4C10-8A54-ADBC661F011A

P698

Q33572246-B1AA644D-C04F-4586-AD7B-DDC498E49F46

P932

Q33572246-DFAEBA7C-854F-415E-9556-32DAA2AB9242

P356

ONCOTARGET.1637

P1433

P1476

Constitutive IDO expression in ...... lving IL-6, STAT3 and the AHR.

@en

P2093

Christian Lutz

http://www.w3.org/2001/XMLSchema#string

Irina Lehmann

http://www.w3.org/2001/XMLSchema#string

Katharina J Rauschenbach

http://www.w3.org/2001/XMLSchema#string

Katharina Ochs

http://www.w3.org/2001/XMLSchema#string

Marcus Winter

http://www.w3.org/2001/XMLSchema#string

Martina Ott

http://www.w3.org/2001/XMLSchema#string

Ulrike M Litzenburger

http://www.w3.org/2001/XMLSchema#string

Wolfgang Wick

http://www.w3.org/2001/XMLSchema#string

Xiangdong Liu

http://www.w3.org/2001/XMLSchema#string

P2860

GATA-3 transcriptional imprinting in Th2 lymphocytes: a mathematical model

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells

STATs in cancer inflammation and immunity: a leading role for STAT3

P304

1038-1051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1637

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Michael Platten

Natasa Anastasov

Christiane Opitz

Andreas von Deimling

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261033717

http://www.w3.org/2001/XMLSchema#string

P698

24657910

http://www.w3.org/2001/XMLSchema#string

P932

4011581

http://www.w3.org/2001/XMLSchema#string